Influenza virus vaccine liposomal - Parkedale
Alternative Names: Fluogen liposomalLatest Information Update: 12 Jan 2004
At a glance
- Originator Parkedale Pharmaceuticals
- Developer Novavax; Parkedale Pharmaceuticals
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 12 Jan 2004 No development reported - Preclinical for Influenza virus infections in USA (unspecified route)
- 17 Oct 2000 Parkedale has discontinued Fluogen®; it is unclear whether this means that development of the liposomal formulation has also been discontinued
- 01 Nov 1999 Preclinical development for Influenza virus infections in USA (Unknown route)